1. Home
  2. EDIT vs YSXT Comparison

EDIT vs YSXT Comparison

Compare EDIT & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • YSXT
  • Stock Information
  • Founded
  • EDIT 2013
  • YSXT 2011
  • Country
  • EDIT United States
  • YSXT China
  • Employees
  • EDIT N/A
  • YSXT N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • YSXT Automotive Aftermarket
  • Sector
  • EDIT Health Care
  • YSXT Consumer Discretionary
  • Exchange
  • EDIT Nasdaq
  • YSXT Nasdaq
  • Market Cap
  • EDIT 99.9M
  • YSXT 87.9M
  • IPO Year
  • EDIT 2016
  • YSXT 2024
  • Fundamental
  • Price
  • EDIT $1.21
  • YSXT $4.78
  • Analyst Decision
  • EDIT Buy
  • YSXT
  • Analyst Count
  • EDIT 14
  • YSXT 0
  • Target Price
  • EDIT $8.08
  • YSXT N/A
  • AVG Volume (30 Days)
  • EDIT 2.7M
  • YSXT 235.9K
  • Earning Date
  • EDIT 02-26-2025
  • YSXT 01-01-0001
  • Dividend Yield
  • EDIT N/A
  • YSXT N/A
  • EPS Growth
  • EDIT N/A
  • YSXT N/A
  • EPS
  • EDIT N/A
  • YSXT 0.21
  • Revenue
  • EDIT $61,759,000.00
  • YSXT $58,546,729.00
  • Revenue This Year
  • EDIT N/A
  • YSXT N/A
  • Revenue Next Year
  • EDIT N/A
  • YSXT N/A
  • P/E Ratio
  • EDIT N/A
  • YSXT $22.45
  • Revenue Growth
  • EDIT 150.95
  • YSXT 18.92
  • 52 Week Low
  • EDIT $1.12
  • YSXT $2.54
  • 52 Week High
  • EDIT $11.58
  • YSXT $6.27
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 34.86
  • YSXT N/A
  • Support Level
  • EDIT $1.15
  • YSXT N/A
  • Resistance Level
  • EDIT $1.27
  • YSXT N/A
  • Average True Range (ATR)
  • EDIT 0.10
  • YSXT 0.00
  • MACD
  • EDIT 0.04
  • YSXT 0.00
  • Stochastic Oscillator
  • EDIT 21.11
  • YSXT 0.00

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares

YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.

Share on Social Networks: